At week 12 , 50 % ( 10 mg ) , 60 % ( 30 and 100 mg ) , and 100 % ( 300 mg ) of guselkumab-treated patients , respectively , achieved a 75 % improvement in PASI scores from baseline compared with 0 % of placebo-treated patients .